Corcept Therapeutics is trading 25% up at $115.95 after reporting a significant second-quarter earnings beat and sharply raising its long-term revenue outlook.
- The company lifted its full-year revenue guidance to a range of $1.1–$1.2 billion, driven by robust growth in its Cushing’s syndrome business.
- Performance was bolstered by the successful launch of the oncology drug Lifyorli and a major upward revision to the company's 2026 revenue projections.